Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
June 06, 2024 11:15 ET
|
Barinthus Biotherapeutics
Barinthus Bio presents updated data from two clinical trials in people with chronic hepatitis B at EASL Congress 2024.
BioNTX Announces 10th Annual iC³® Life Science & Healthcare Innovation Summit
June 06, 2024 10:00 ET
|
Bio North Texas
BioNTX, the leading biotechnology trade organization in North Texas, is thrilled to announce the 10th Annual iC³® Life Science Summit.
Qu Biologics and Foundation Medicine Collaborate to Impact the Care of Patients with Late-Stage Colorectal Cancer
June 06, 2024 08:00 ET
|
Qu Biologics, Inc.
BURNABY, British Columbia, June 06, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
Global Metabolomics Report 2024: Market Poised for Substantial Growth, Expected to Reach $6.5 Billion by 2032, Fueled by Advancements in Personalized Medicine and Chronic Disease Prevalence
June 06, 2024 04:06 ET
|
Research and Markets
Dublin, June 06, 2024 (GLOBE NEWSWIRE) -- The "Global Metabolomics Market Report by Product, Indication, Application, and Region 2024-2032" report has been added to ResearchAndMarkets.com's...
Mushrooms Inc. (OTC: MSRM) Announces Significant Share Buy Back by the Board Director and New Strategic Initiatives
June 05, 2024 18:19 ET
|
Mushrooms Inc.
ESTERO, Fla., June 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Mushrooms Inc. (OTC: MSRM), a leading innovator in biotechnology and sustainable healthcare solutions using mushrooms and mycelium, is...
Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference
June 05, 2024 16:15 ET
|
Mural Oncology, Inc.
WALTHAM, Mass. and DUBLIN, June 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
Osteal Therapeutics Closes $50M Series D Financing to Support Approval and Commercial Launch of Lead Candidate
June 05, 2024 09:00 ET
|
Osteal Therapeutics
Osteal Therapeutics secured $50M in Series D financing led by Zimmer Biomet. The funds will advance VT-X7, a treatment for periprosthetic joint infection.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2024 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 31, 2024 it granted stock options to purchase an aggregate of...
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
June 04, 2024 09:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of...
Generation Food Rural Partners Launches BioCloak to Enable Truly Sustainable Active Ingredient Encapsulation, Appoints CEO
June 04, 2024 09:00 ET
|
Big Idea Ventures, LLC
Generation Food Rural Partners Launches BioCloak to Enable Truly Sustainable Active Ingredient Encapsulation, Appoints CEO